![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NITTO DENKO AND ISIS PHARMACEUTICALS ANNOUNCE HIGH-PERFORMANCE CROSS-LINKED POLYSTYRENE BEAD
NITTO DENKO AND ISIS PHARMACEUTICALS ANNOUNCE HIGH-PERFORMANCE CROSS-LINKED POLYSTYRENE BEAD
Nitto Denko and Nitto Denko Technical, a dedicated R&D facility in Oceanside, Calif., have announced development of a high-performance cross-linked polystyrene bead which can support a high-grade, high-yield synthesis of oligonucleotides, essential to DNA and RNA-based gene therapies, and provide solid support for the synthesis of antisense drugs. The development was achieved in a joint venture with Isis Pharmaceuticals, a U.S. company that was the first in the world to succeed in bringing an antisense drug (a gene-repair therapy) to market.
Japan Corporate News (http://www.japancorp.net/Article.Asp?Art_ID=9112)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct